These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 34689233)

  • 1. Real-world outcomes of regorafenib combined with immune checkpoint inhibitors in patients with advanced or metastatic microsatellite stable colorectal cancer: A multicenter study.
    Yang K; Han L; Wu S; Qu X; Li Q; Zhao C; Zhou J; Jin X; Wang Y; Yan D; Cheng Z; Hua Y; Zhang Y; Ge Y; Sun J; Deng W; Zhao L; Zhao Y
    Cancer Immunol Immunother; 2022 Jun; 71(6):1443-1451. PubMed ID: 34689233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regorafenib monotherapy or combined with an immune-checkpoint inhibitor as later-line treatment for metastatic colorectal cancer: a multicenter, real-world retrospective study in China.
    Qu W; Liu Z; Chen X; Liu B; Zhao Y; Yan H; Qu X; Li S; Zang A; Sun Y; Zhu L; Zhou A
    BMC Cancer; 2024 Jan; 24(1):22. PubMed ID: 38166647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regorafenib and Nivolumab or Pembrolizumab Combination and Circulating Tumor DNA Response Assessment in Refractory Microsatellite Stable Colorectal Cancer.
    Wang C; Chevalier D; Saluja J; Sandhu J; Lau C; Fakih M
    Oncologist; 2020 Aug; 25(8):e1188-e1194. PubMed ID: 32406541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regorafenib, Ipilimumab, and Nivolumab for Patients With Microsatellite Stable Colorectal Cancer and Disease Progression With Prior Chemotherapy: A Phase 1 Nonrandomized Clinical Trial.
    Fakih M; Sandhu J; Lim D; Li X; Li S; Wang C
    JAMA Oncol; 2023 May; 9(5):627-634. PubMed ID: 36892833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Refractory microsatellite stable metastatic colorectal cancer with ERBB2/ERBB3 mutation may be preferred population for regorafenib plus PD-1 inhibitor therapy: a real-world study.
    Dai X; Ding W; He Y; Huang S; Liu Y; Wu T
    Front Oncol; 2023; 13():1227644. PubMed ID: 37681031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world effectiveness of regorafenib in the treatment of patients with metastatic colorectal cancer: A retrospective, observational study.
    Wang H; Liu W; Zhao Y; Hu H; Zhang B; Yang S
    Asia Pac J Clin Oncol; 2023 Oct; 19(5):e291-e299. PubMed ID: 36572661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regorafenib with immunotherapy versus regorafenib alone as second-line treatment for hepatocellular carcinoma: A multicenter real-world study.
    Qiao L; He W; Wang G; Chen H; Huang F; Zhang B; Qiu Y; Liu S; Huang Z; Yuan Y; Qiu J; Yuan Y; Li B
    Cancer Med; 2024 May; 13(9):e7236. PubMed ID: 38716585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver Metastases and Immune Checkpoint Inhibitor Efficacy in Patients With Refractory Metastatic Colorectal Cancer: A Secondary Analysis of a Randomized Clinical Trial.
    Chen EX; Loree JM; Titmuss E; Jonker DJ; Kennecke HF; Berry S; Couture F; Ahmad CE; Goffin JR; Kavan P; Harb M; Colwell B; Samimi S; Samson B; Abbas T; Aucoin N; Aubin F; Koski S; Wei AC; Tu D; O'Callaghan CJ
    JAMA Netw Open; 2023 Dec; 6(12):e2346094. PubMed ID: 38051531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination chemotherapy with Regorafenib in metastatic colorectal cancer treatment: A single center, retrospective study.
    Lin CY; Lin TH; Chen CC; Chen MC; Chen CP
    PLoS One; 2018; 13(1):e0190497. PubMed ID: 29304109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of immune checkpoint inhibitors in combination with tyrosine kinase inhibitors in patients with advanced or metastatic colorectal carcinoma with either mismatch repair proficient or metastatic microsatellite stable disease: A systematic review and meta‑analysis.
    Li J; Zhu JX; Zhang YX; Li SQ
    Oncol Lett; 2024 Apr; 27(4):153. PubMed ID: 38406596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of regorafenib in the treatment of metastatic colorectal cancer: a retrospective cohort study.
    Yan H; Liu J; Zhang Y; Chen S; Xu J; Gao D; Li H; Fang X; Wang Y; Wang H; Wang H
    J Gastrointest Oncol; 2024 Jun; 15(3):987-1001. PubMed ID: 38989408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Key Prognostic Factors Create a Composite Risk Score to Stratify Patients into High- and Low-Treatment Benefit Groups: A Multicenter, Retrospective Data Analysis of 84 Metastatic Colorectal Cancer Patients Treated with Regorafenib as Part of the CORRECT and CONSIGN Trials.
    Zöhrlaut LK; Karthaus M; Vehling-Kaiser U; von Kunhardt L; Stintzing S; Heinemann V; von Einem JC
    Oncol Res Treat; 2023; 46(9):348-361. PubMed ID: 37607525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy response in microsatellite stable metastatic colorectal cancer is influenced by site of metastases.
    Fakih M; Wang C; Sandhu J; Ye J; Egelston C; Li X
    Eur J Cancer; 2024 Jan; 196():113437. PubMed ID: 37980853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Efficacy of Immune Checkpoint Inhibitors in Microsatellite Stable Colorectal Cancer: A Systematic Review.
    Guven DC; Kavgaci G; Erul E; Syed MP; Magge T; Saeed A; Yalcin S; Sahin IH
    Oncologist; 2024 May; 29(5):e580-e600. PubMed ID: 38309719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer.
    Taşçı EŞ; Oyan B; Sönmez Ö; Mutlu AU; Atcı MM; Sakin A; Öner İ; Çınkır HY; Eryılmaz MK; Çağlayan D; Balçık OY; Paksoy N; Karabulut S; Salim DK; Bilir C; Özen M; Özçelik M; Arıcan A; Akagündüz B; İnal A; Aydın D; Özer L; Gülmez A; Turhal NS; Esen SA; Algın E; Akbaş S; İriağaç Y; Şakalar T; Ünal Ç; Er Ö; Seçmeler Ş; Bozkurt M
    BMC Cancer; 2024 Jan; 24(1):16. PubMed ID: 38166764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety analysis of a HER2-targeting antibody-drug conjugate combined with immune checkpoint inhibitors in solid tumors: a real-world study.
    Zhou YX; Wang JL; Mu XL; Zhu YJ; Chen Y; Liu JY
    Aging (Albany NY); 2023 Dec; 15(24):15473-15488. PubMed ID: 38147019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of immune checkpoint inhibitors for metastatic colorectal cancer with microsatellite instability in second or latter line using synthetic control arms: A non-randomised evaluation.
    Cohen R; Raeisi M; Chibaudel B; Yoshino T; Shi Q; Zalcberg JR; Adams R; Cremolini C; Grothey A; Mayer RJ; Van Cutsem E; Tabernero J; Bando H; Misumi T; Overman MJ; André T; de Gramont A
    Eur J Cancer; 2024 Mar; 199():113537. PubMed ID: 38241818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Severe hypertension development significantly improves progression-free survival in regorafenib treatment for metastatic colorectal cancer.
    Saito Y; Takekuma Y; Komatsu Y; Sugawara M
    Int J Clin Oncol; 2023 Sep; 28(9):1183-1190. PubMed ID: 37322220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy comparison of fruquintinib, regorafenib monotherapy or plus programmed death-1 inhibitors for microsatellite stable metastatic colorectal cancer.
    An TQ; Qiu H; Zhou QB; Zong H; Hu S; Lian YG; Zhao RH
    World J Gastrointest Oncol; 2024 Jun; 16(6):2449-2462. PubMed ID: 38994132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metastatic site and clinical outcome of patients with deficient mismatch repair metastatic colorectal cancer treated with an immune checkpoint inhibitor in the first-line setting.
    Saberzadeh-Ardestani B; Jones JC; McWilliams RR; Tougeron D; Halfdanarson TR; Guimbaud R; Hubbard JM; Flecchia C; Shi Q; Alouani E; Sonbol MB; Ticku J; Jin Z; Taieb J; Sinicrope FA
    Eur J Cancer; 2024 Jan; 196():113433. PubMed ID: 37979306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.